Trial · NCT04074317
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Area Under the Curve 0-180 Minutes for Plasma Glucose >180 mg/dL | 0-180 minutes following administration of study drug | The number of participants analyzed were the number of participants with glucose \>180 mg/dL. | min*mg/dL | MEAN |
| SECONDARY | Mean Proportional Time for Plasma Glucose Levels | Up to 360 minutes following administration of study drug | The number of participants analyzed were the number of participants 0 to 90, 0 to 180, and 0 to 360 minutes after study drug administration with any evaluable plasma glucose concentration data. (While the number of participants noted for each datapoint had evaluable plasma glucose concentration data, not all of the participants had values in the range of plasma glucose concentration required for the analysis of the proportion of time with glucose concentrations in the specified range.) | percentage of time | MEAN |
| SECONDARY | Mean Proportional Time After Glucose Challenge for Plasma Glucose Levels Between 126 to 180 mg/dL | During 40 to 180 minutes post-injection of study drug | The number of participants analyzed were the number of participants 0 to 90, 0 to 180, and 0 to 360 minutes after study drug administration with any evaluable plasma glucose concentration data. (While the number of participants noted for each data point had evaluable plasma glucose concentration data, not all of the participants had values in the range of plasma glucose concentration required for the analysis of the proportion of time with glucose concentrations in the specified range.) | percentage of time | MEAN |
| SECONDARY | Area Under the Concentration (AUC) Curve for Plasma Glucose | Up to 360 minutes following administration of study drug | The number of participants analyzed were the number of participants after study drug administration with evaluable glucose measurements.~(The time period of 0 to 90 minutes after study drug administration with glucose \>250 mg/dL was not quantifiable.) | min*mg/dL | MEAN |
| SECONDARY | Area Over the Concentration (AOC) Curve for Plasma Glucose | Up to 360 minutes following administration of study drug | The number of participants analyzed were the number of participants after study drug administration with evaluable glucose measurements.~(There was no data available for the analysis of AOC0-90 for plasma glucose \<54 mg/dL.) | min*mg/dL | MEAN |
| SECONDARY | Plasma Glucose Cmax | Up to 360 minutes following administration of study drug | The number of participants analyzed were the number of participants after study drug administration with evaluable glucose measurements. | mg/dL | MEAN |
| SECONDARY | Plasma Glucose Tmax | Up to 360 minutes following administration of study drug | The number of participants analyzed were the number of participants after study drug administration with evaluable glucose measurements. | minutes | MEAN |
| SECONDARY | Pramlintide Cmax | Up to 360 minutes following administration of study drug | The number of participants analyzed were the number of participants after study drug administration with evaluable pramlintide measurements. | pg/mL | MEAN |
| SECONDARY | Pramlintide Tmax | Up to 360 minutes following administration of study drug | The number of participants analyzed were the number of participants after study drug administration with evaluable pramlintide concentrations. | minutes | MEDIAN |
| SECONDARY | Pramlintide Area Under the Concentration (AUC) Curve | Up to 360 minutes following administration of study drug | The number of participants analyzed were the number of participants after study drug administration with evaluable pramlintide concentrations. | min*pg/mL | MEAN |
| SECONDARY | Insulin Cmax | Up to 360 minutes following administration of study drug | The number of participants analyzed were the number of participants after study drug administration with evaluable insulin measurements. | pg/mL | MEAN |
| SECONDARY | Insulin Tmax | Up to 360 minutes following administration of study drug | The number of participants analyzed were the number of participants after study drug administration with evaluable insulin concentrations. | minutes | MEDIAN |
| SECONDARY | Insulin Area Under the Concentration (AUC) Curve | Up to 360 minutes following administration of study drug | The number of participants analyzed were the number of participants after study drug administration with evaluable insulin concentrations. | min*pg/mL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04074317/outcomes